Work

Abstract CT113: A first-in-human phase 1, multicenter, open-label study of M3554, a novel anti-GD2 antibody-drug conjugate (ADC), in patients with advanced solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct113

Authors: Antoine Italiano, Kan Yonemori, Candace L. Haddox, Jordi R. Ahnert, Nicolas Penel, Patrick Schöffski, Christina Habermehl, Vanesa P. Sanz, George Demetri

Institutions: Institut Bergonié, National Cancer Center Hospital, Harvard University, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Université de Lille, Centre Oscar Lambret, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Dana-Farber/Harvard Cancer Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822350

Cites:

Cited by: 2

Related to: 10